The Beauty Health shares up 20.73% intraday after reporting Q4 2025 sales and EBITDA above estimates and shifting strategy to boost equipment utilization and consumables revenue.

The Beauty Health surged 20.73% intraday, driven by the company's Q4 2025 results showing $82.4 million in sales (exceeding estimates of $77.8 million) and adjusted EBITDA of $15 million (far above expected $8.26 million). The firm also announced a strategic shift to enhance equipment utilization, boosting consumables revenue to $57.7 million (+1.7%) with over 36,000 installed systems, alongside 2026 guidance projecting $285–305 million in net sales and adjusted EBITDA of $35–45 million.